| PERIOD ENDING | 30-Jun-02 | 31-Mar-02 | | Total Revenue | 5,235 | 4,421 | | Cost of Revenue | 3,149 | 2,226 | | | Gross Profit | 2,086 | 2,195 | | | Operating Expenses | | Research Development | 915 | 1,036 | | Selling General and Administrative | 2,131 | 2,167 | | Non Recurring |
-
|
-
| | Others | 47 | 20 | | | | Total Operating Expenses |
-
|
-
| | | | Operating Income or Loss | (1,007) | (1,028) | | | Income from Continuing Operations | | Total Other Income/Expenses Net | (905) | 359 | | Earnings Before Interest And Taxes | (1,912) | (669) | | Interest Expense | (240) | 240 | | Income Before Tax | (1,672) | (909) | | Income Tax Expense | (19) | 22 | | Minority Interest |
-
| (19) | | | | Net Income From Continuing Ops | (1,653) | (950) | | | Non-recurring Events | | Discontinued Operations |
-
|
-
| | Extraordinary Items | 287 | (287) | | Effect Of Accounting Changes |
-
|
-
| | Other Items |
-
|
-
| | | | Net Income | (1,366) | (1,237) | | Preferred Stock And Other Adjustments |
-
|
-
| | | Net Income Applicable To Common Shares | ($1,366) | ($1,237) |
|
0.51% Nasdaq 0.00%
Income Statement
